전남대학교 중앙도서관

  • 중앙도서관
  • 여수캠퍼스도서관
  • 법학도서관
  • 치의학도서관
  • 의학도서관

링크메뉴

  • 화면키우기 화면줄이기 화면크기 원래대로
  • S
  • HOME
  • 로그인
  • 전남대
  • ENG
  • CHN

주메뉴

전체메뉴

전자자료 상세검색

전자자료 상세검색

통합검색
상세검색
검색어 [키워드: "Parikh, O"]
총 60건 
※ 페이지 이동 시, 중복 레코드가 제거되므로 초기 검색결과 수와 차이가 있을 수 있습니다.
6/6 페이지 RSS 엑셀파일 출력
검색결과수정
  • 검색범위확장
    • Full Text내 키워드 확장
    • 관련 주제어 확장

    재검색

  • 검색결과제한
    • 원문(Full Text)
    • Peer-Reviewed 학술지
    • 발행년 -

    재검색

  • 자료유형
    • Academic Journals (94)
    • Magazines (4)
    • eBooks (3)

    재검색

  • 주제
    • prostatic neoplasms (11)
    • prostatic neoplasms, castration-resistant (8)
    • antineoplastic combined chemotherapy protocols (6)

    더보기

    재검색

  • 간행물
    • clinical oncology (31)
    • annals of oncology (12)
    • radiotherapy and oncology (7)

    더보기

    재검색

  • 출판사
    • elsevier b.v. (17)
    • elsevier ltd (14)
    • elsevier (11)

    더보기

    재검색

  • 언어
    • english (92)
    • french (2)

    재검색

  • Publication Year
    • 2023 (3)
    • 2017 (2)
    • 2011 (1)

    더보기

    재검색

  • 수록데이터베이스
    • MEDLINE (30)
    • Science Citation Index Expanded (23)
    • ScienceDirect (19)

    더보기

    재검색

  • PQDTSearch
  • CAJSearch
  • RISSSearch
  • PsycINFOSearch

 

51
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. 미리보기

학술저널

issue
Cells [Cells] 2021 Dec 22; Vol. 11 (1). Date of Electronic Publication: 2021 Dec 22.
Author
Oudard S; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.; APHP, Service de Cancérologie, Hôpital Européen Georges Pompidou, Université de Paris, 75908 Paris, France.
Benhamouda N; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Escudier B; Department of Medical Oncology, Institut Gustave Roussy, CEDEX, 94805 Villejuif, France.
Ravel P; Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, Université Montpellier, CEDEX 5, 34298 Montpellier, France.
Tran T; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Levionnois E; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Negrier S; Centre Léon Bérard Lyon, University Lyon 1, 69008 Lyon, France.
Barthelemy P; Institut de Cancérologie Strasbourg Europe, Strasbourg University Hospital, 67200 Strasbourg, France.
Berdah JF; Medical Oncology Unit, Hôpital Privé Toulon-Hyères, Sainte-Marguerite, 83400 Hyeres, France.
Gross-Goupil M; Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 31000 Bordeaux, France.
Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer, New York, NY 10065, USA.
Bono P; Kamppi Hospital Department, Terveystalo Finland, 00100 Helsinki, Finland.
Porta C; Division of Translational Oncology, IRCCS San Matteo University Hospital, 27100 Pavia, Italy.; Division of Oncology, Policlinico Consorziale di Bari, University of Bari 'A. Moro', 70121 Bari, Italy.
De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy.
Parikh O; Department of Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK.
Hawkins R; Institute of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.
Highley M; Oncology Centre, Derriford Hospital, Plymouth PL6 8DH, UK.
Wilke J; Gemeinschaftspraxis Dres. Wilke/Wagner/Petzoldt, 90766 Fuerth, Germany.
Decker T; Studienzentrum Onkologie, Practice for Hematology and Oncology, 88212 Ravensburg, Germany.
Tanchot C; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Gey A; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Terme M; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
Tartour E; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France.
DB Label
Database : MEDLINE
원문보기
Full Text Full Text (원문보기) PLinkFull Text (원문보기) Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
53
Genomics of lethal prostate cancer at diagnosis and castration resistance. 미리보기

학술저널

issue
The Journal of clinical investigation [J Clin Invest] 2020 Apr 01; Vol. 130 (4), pp. 1743-1751.
Author
Mateo J; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Seed G; The Institute of Cancer Research, London, United Kingdom.
Bertan C; The Institute of Cancer Research, London, United Kingdom.
Rescigno P; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Dolling D; The Institute of Cancer Research, London, United Kingdom.
Figueiredo I; The Institute of Cancer Research, London, United Kingdom.
Miranda S; The Institute of Cancer Research, London, United Kingdom.
Nava Rodrigues D; The Institute of Cancer Research, London, United Kingdom.
Gurel B; The Institute of Cancer Research, London, United Kingdom.
Clarke M; The Institute of Cancer Research, London, United Kingdom.
Atkin M; The Institute of Cancer Research, London, United Kingdom.
Chandler R; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Messina C; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Sumanasuriya S; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Bianchini D; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Barrero M; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Petermolo A; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Zafeiriou Z; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Fontes M; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.; Instituto Oncoclinicas-Grupo Oncoclinicas, Rio de Janeiro, Brazil.
Perez-Lopez R; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Tunariu N; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Fulton B; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Jones R; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
McGovern U; University College Hospital, London, United Kingdom.
Ralph C; St James's University Hospital, Leeds, United Kingdom.
Varughese M; Musgrove Park Hospital, Taunton, United Kingdom.
Parikh O; Royal Blackburn Hospital, Blackburn, United Kingdom.
Jain S; Belfast City Hospital, Belfast, United Kingdom.
Elliott T; The Christie Hospital, Manchester, United Kingdom.
Sandhu S; Peter McCallum Cancer Center, Melbourne, Australia.
Porta N; The Institute of Cancer Research, London, United Kingdom.
Hall E; The Institute of Cancer Research, London, United Kingdom.
Yuan W; The Institute of Cancer Research, London, United Kingdom.
Carreira S; The Institute of Cancer Research, London, United Kingdom.
de Bono JS; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
54
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. 미리보기

학술저널

issue
The Lancet. Oncology [Lancet Oncol] 2020 Jan; Vol. 21 (1), pp. 162-174. Date of Electronic Publication: 2019 Dec 02.
Author
Mateo J; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Porta N; The Institute of Cancer Research, London, UK.
Bianchini D; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
McGovern U; University College Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
Elliott T; The Christie NHS Foundation Trust, Manchester, UK.
Jones R; University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, UK.
Syndikus I; The Clatterbridge Cancer Centre, Wirral, UK.
Ralph C; St James's Institute of Oncology, University of Leeds, Leeds, UK.
Jain S; Queen's University, Belfast, UK.
Varughese M; Musgrove Park Hospital, Taunton, UK.
Parikh O; Royal Blackburn Hospital, Blackburn, UK.
Crabb S; University of Southampton, Southampton, UK.
Robinson A; Royal Sussex County Hospital, Brighton, UK.
McLaren D; Western General Hospital, Edinburgh, UK.
Birtle A; Royal Lancaster Infirmary, Lancaster, UK.
Tanguay J; Velindre Cancer Centre, Cardiff, UK.
Miranda S; The Institute of Cancer Research, London, UK.
Figueiredo I; The Institute of Cancer Research, London, UK.
Seed G; The Institute of Cancer Research, London, UK.
Bertan C; The Institute of Cancer Research, London, UK.
Flohr P; The Institute of Cancer Research, London, UK.
Ebbs B; The Institute of Cancer Research, London, UK.
Rescigno P; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Fowler G; The Institute of Cancer Research, London, UK.
Ferreira A; The Institute of Cancer Research, London, UK.
Riisnaes R; The Institute of Cancer Research, London, UK.
Pereira R; The Institute of Cancer Research, London, UK.
Curcean A; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Chandler R; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Clarke M; The Institute of Cancer Research, London, UK.
Gurel B; The Institute of Cancer Research, London, UK.
Crespo M; The Institute of Cancer Research, London, UK.
Nava Rodrigues D; The Institute of Cancer Research, London, UK.
Sandhu S; Peter McCallum Cancer Center, Melbourne, VIC, Australia.
Espinasse A; The Institute of Cancer Research, London, UK.
Chatfield P; The Institute of Cancer Research, London, UK.
Tunariu N; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Yuan W; The Institute of Cancer Research, London, UK.
Hall E; The Institute of Cancer Research, London, UK.
Carreira S; The Institute of Cancer Research, London, UK.
de Bono JS; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.
DB Label
Database : MEDLINE
원문보기
Full Text (ScienceDirect)  Full Text (Clinical Key)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
55
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. 미리보기

학술저널

issue
European urology oncology [Eur Urol Oncol] 2018 Dec; Vol. 1 (6), pp. 449-458. Date of Electronic Publication: 2018 Sep 14.
Author
Woods BS; Centre for Health Economics, University of York, York, UK. Electronic address: beth.woods@york.ac.uk.
Sideris E; Centre for Health Economics, University of York, York, UK.
Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Gannon MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Alzouebi M; Weston Park Hospital, Sheffield, UK.
Attard G; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Birtle AJ; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
Brock S; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK.
Cathomas R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Kantonsspital Graubünden, Chur, Switzerland.
Chakraborti PR; Royal Derby Hospital, Derby, UK.
Cook A; Gloucestershire Oncology Centre, Cheltenham, UK.
Cross WR; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Dearnaley DP; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK.
Gibbs S; Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK.
Hughes R; Mount Vernon Group, Mount Vernon Hospital, Northwood, UK.
Jones RJ; University of Glasgow, UK.
Laing R; St Luke's Cancer Centre, Royal Surrey NHS Trust, Guildford, UK.
Mason MD; School of Medicine, Cardiff University, Cardiff, UK.
Matheson D; University of Wolverhampton, Wolverhampton, UK.
McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK.
Millman R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, Burnley, UK.
Parker CC; The Royal Marsden NHS Foundation Trust, London, UK.
Peedell C; South Tees NHS Foundation Trust, Middlesbrough, UK.
Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK.
Ritchie AWS; Gloucestershire Royal Hospital Foundation Trust, Gloucester, UK.
Robinson A; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK.
Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Forth Valley Royal Hospital, Larbert, UK.
Simms MS; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
Srihari NN; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK.
Srinivasan R; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Staffurth JN; Velindre Cancer Centre, Cardiff and School of Medicine, Cardiff University, Cardiff, UK.
Sundar S; University of Nottingham, Nottingham, UK.
Thalmann GN; Department of Urology, University Hospital Bern, Bern, Switzerland.
Tolan S; Clatterbridge Cancer Centre, Birkenhead, UK.
Tran ATH; The Christie NHS Foundation Trust, Manchester, UK.
Tsang D; Southend and Basildon Hospitals, Southend, UK.
Wagstaff J; Swansea University College of Medicine, Swansea, UK.
James ND; Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Sculpher MJ; Centre for Health Economics, University of York, York, UK.
DB Label
Database : MEDLINE
원문보기
Full Text (ScienceDirect)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
57
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 미리보기

학술저널

issue
Lancet (London, England) [Lancet] 2016 Mar 19; Vol. 387 (10024), pp. 1163-77. Date of Electronic Publication: 2015 Dec 21.
Author
James ND; Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
Sydes MR; MRC Clinical Trials Unit at UCL, London, UK. Electronic address: m.sydes@ucl.ac.uk.
Clarke NW; Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
Mason MD; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
Dearnaley DP; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Spears MR; MRC Clinical Trials Unit at UCL, London, UK.
Ritchie AW; MRC Clinical Trials Unit at UCL, London, UK.
Parker CC; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Russell JM; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Attard G; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
de Bono J; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
Cross W; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds.
Jones RJ; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Thalmann G; Department of Urology, University Hospital, Bern, Switzerland.
Amos C; MRC Clinical Trials Unit at UCL, London, UK.
Matheson D; Patient rep, MRC Clinical Trials Unit at UCL, London, UK.
Millman R; Patient rep, MRC Clinical Trials Unit at UCL, London, UK.
Alzouebi M; Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK.
Beesley S; Kent Oncology Centre, Maidstone Hospital, Maidstone, UK.
Birtle AJ; Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
Brock S; Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland.
Cathomas R; Kantonsspital Graubünden, Chur, Switzerland.
Chakraborti P; Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK.
Chowdhury S; Department of Medical Oncology, Guy's Hospital, London, UK.
Cook A; Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK.
Elliott T; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Gale J; Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK.
Gibbs S; Department of Oncology, Queen's Hospital, Romford, UK.
Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK.
Hetherington J; Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
Hughes R; Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK.
Laing R; Department of Oncology, Royal Surrey County Hospital, Guildford, UK.
McKinna F; Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK.
McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK.
O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK.
Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK.
Peedell C; Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK.
Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK.
Robinson AJ; Department of Oncology, Sussex Cancer Centre, Brighton, UK.
Srihari N; Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK.
Srinivasan R; Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK.
Staffurth J; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
Sundar S; Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK.
Tolan S; Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK.
Tsang D; Department of Oncology, Southend & Basildon Hospitals, Essex, UK.
Wagstaff J; The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK.
Parmar MK; MRC Clinical Trials Unit at UCL, London, UK.
DB Label
Database : MEDLINE
원문보기
Full Text (ScienceDirect)  Full Text (Clinical Key)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
58
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. 미리보기

학술저널

issue
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 May 10; Vol. 32 (14), pp. 1412-8. Date of Electronic Publication: 2014 Mar 31.
Author
Escudier B; Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N. Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E. Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.
Porta C
Bono P
Powles T
Eisen T
Sternberg CN
Gschwend JE
De Giorgi U
Parikh O
Hawkins R
Sevin E
Négrier S
Khan S
Diaz J
Redhu S
Mehmud F
Cella D
DB Label
Database : MEDLINE
원문보기
등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
60
Purpura fulminans. 미리보기

보고서

issue
Indian journal of dermatology, venereology and leprology [Indian J Dermatol Venereol Leprol] 1988 Jan-Feb; Vol. 54 (1), pp. 30-32.
Author
Parikh OA
Fernandez RJ
Bhatia SJ
Karand DR
Dastur FD
DB Label
Database : MEDLINE
원문보기
등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
  6 
바구니보기

QUICK LINK

  • 희망도서신청
  • 대출/연장조회
  • 서가부재도서
  • 이용교육

마이메뉴추가

QRCode
  • 개인정보호정책
  • 이메일무단수집거부
  • 도서관이용문의

    • 도서관자치위원회  원격제어  Instagram  facebook  w  kakao 플친
500-757 광주광역시 북구 용봉로 77 TEL 062)530-3571~2(대출반납실) FAX 062)530-3529
Copyright@2013 CHONNAM NATIONAL UNIVERSITY LIBRARY, All Rights Reserved.
  • 120181
  • 127131102